Home › Funds › PERCEPTIVE ADVISORS LLC › PTGX

PERCEPTIVE ADVISORS LLC position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

PERCEPTIVE ADVISORS LLC reported holding 981,879 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$120.4M, representing 1.91% of its reported portfolio and ranking #16 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed PTGX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)981.88K sh
Reported value held$120.36M
Portfolio Weight1.91%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PERCEPTIVE ADVISORS LLC's PTGX position evolved

PERCEPTIVE ADVISORS LLC first disclosed a stake in PTGX in Q3 2023 at 1,054,273 shares (US$17.6M). The position peaked in Q1 2026 at 1,230,879 shares, worth US$129.7M. Across 12 filings, PERCEPTIVE ADVISORS LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 981,879 shares valued at US$120.4M — a reduction of -249,000 shares quarter over quarter.. Notable position changes include a 64% trim in Q4 2023 (shares rose 26% over the following quarter), a 159% increase in Q1 2024 (shares rose 20% over the following quarter), a 31% increase in Q4 2025 (shares rose 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.05M $17.59M New
Q4 2023 383.26K $8.79M Reduce
Q1 2024 994.32K $28.77M Add
Q2 2024 1.27M $43.96M Add
Q3 2024 1.37M $61.86M Add
Q4 2024 1.27M $49.09M Reduce
Q1 2025 1.09M $52.77M Reduce
Q2 2025 1.07M $59.38M Reduce
Q3 2025 1.03M $68.43M Reduce
Q4 2025 1.35M $117.95M Add
Q1 2026 1.23M $129.73M Reduce
Q2 2026 981.88K $120.36M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has PERCEPTIVE ADVISORS LLC held PTGX?

PERCEPTIVE ADVISORS LLC has disclosed PTGX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is PERCEPTIVE ADVISORS LLC's current position in PTGX?

As of Q2 2026, PERCEPTIVE ADVISORS LLC holds 981.88K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $120.36M, representing 1.91% of its reported portfolio and ranking #16.

Has PERCEPTIVE ADVISORS LLC been buying or selling PTGX?

In the latest 13F filing (Q2 2026), PERCEPTIVE ADVISORS LLC reduced its position in PTGX. The position peaked in Q1 2026 at 1.23M shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.